[go: up one dir, main page]

ECSP21078204A - Compuestos y conjugados de estos - Google Patents

Compuestos y conjugados de estos

Info

Publication number
ECSP21078204A
ECSP21078204A ECSENADI202178204A ECDI202178204A ECSP21078204A EC SP21078204 A ECSP21078204 A EC SP21078204A EC SENADI202178204 A ECSENADI202178204 A EC SENADI202178204A EC DI202178204 A ECDI202178204 A EC DI202178204A EC SP21078204 A ECSP21078204 A EC SP21078204A
Authority
EC
Ecuador
Prior art keywords
linker
conjugates
compounds
unit
ligand unit
Prior art date
Application number
ECSENADI202178204A
Other languages
English (en)
Inventor
Philip Howard
William Goundry
Thais Cailleau
Luke Masterson
Niall Dickinson
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69960637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21078204(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of ECSP21078204A publication Critical patent/ECSP21078204A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detail Structures Of Washing Machines And Dryers (AREA)

Abstract

Un conjugado que comprende el siguiente derivado de un inhibidor de la topoisomerasa (A*): con un conector para la unión a una Unidad de Ligando, donde el conector está enlazado de una forma escindible al residuo amínico. La Unidad de Ligando es preferentemente un anticuerpo. También se proporciona A* con la unidad conectora enlazada e intermedios para su síntesis, así como también la carga útil liberada.
ECSENADI202178204A 2019-03-29 2021-10-22 Compuestos y conjugados de estos ECSP21078204A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826393P 2019-03-29 2019-03-29
US202062964177P 2020-01-22 2020-01-22

Publications (1)

Publication Number Publication Date
ECSP21078204A true ECSP21078204A (es) 2021-11-30

Family

ID=69960637

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202178204A ECSP21078204A (es) 2019-03-29 2021-10-22 Compuestos y conjugados de estos

Country Status (29)

Country Link
US (3) US20200306243A1 (es)
EP (2) EP4176904A1 (es)
JP (2) JP7210770B2 (es)
KR (3) KR102679892B1 (es)
CN (4) CN113631196B (es)
AU (1) AU2020252034B2 (es)
BR (1) BR112021018986A2 (es)
CA (1) CA3133757A1 (es)
CL (1) CL2021002498A1 (es)
CO (1) CO2021014566A2 (es)
CR (1) CR20210541A (es)
DK (1) DK3946464T3 (es)
EC (1) ECSP21078204A (es)
ES (1) ES2930295T3 (es)
HR (1) HRP20221280T1 (es)
HU (1) HUE060364T2 (es)
IL (1) IL286291B2 (es)
LT (1) LT3946464T (es)
MX (1) MX2021011812A (es)
PH (1) PH12021552363A1 (es)
PL (1) PL3946464T3 (es)
PT (1) PT3946464T (es)
RS (1) RS63715B1 (es)
SG (1) SG11202110524VA (es)
SM (1) SMT202200439T1 (es)
TW (2) TWI886667B (es)
UA (1) UA129129C2 (es)
WO (1) WO2020200880A1 (es)
ZA (1) ZA202106612B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019306658A1 (en) 2018-07-20 2021-01-07 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
US11493668B2 (en) 2018-09-26 2022-11-08 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
KR102679892B1 (ko) * 2019-03-29 2024-07-02 메디뮨 리미티드 화합물 및 이의 접합체
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
WO2021148500A1 (en) * 2020-01-22 2021-07-29 Medimmune Limited Compounds and conjugates thereof
KR20250119655A (ko) * 2021-02-05 2025-08-07 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 캄프토테신 화합물, 그의 제조방법 및 그의 응용
WO2023020531A1 (zh) 2021-08-17 2023-02-23 江苏迈威康新药研发有限公司 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物
CN118414339A (zh) 2021-12-16 2024-07-30 迈威(上海)生物科技股份有限公司 一种喜树碱类化合物及其偶联物
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
CR20240415A (es) 2022-03-09 2024-11-07 Astrazeneca Ab MOLÉCULAS DE UNIÓN CONTRA FRa
AU2023229967A1 (en) 2022-03-11 2024-08-08 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
MX2024011518A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el tratamiento de tumores que expresan ptk7.
EP4496593A1 (en) 2022-03-23 2025-01-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
JP2025510700A (ja) 2022-03-23 2025-04-15 シンアフィックス ビー．ブイ． Ｔｒｏｐ－２を発現する腫瘍を標的化するための抗体コンジュゲート
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
IL315393A (en) 2022-03-25 2024-11-01 Zymeworks Bc Inc Antibody preparations for drugs targeting alpha acid receptor and methods of use
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
WO2024170660A1 (en) 2023-02-16 2024-08-22 Astrazeneca Ab Combination therapies for treatment of cancer with therapeutic binding molecules
WO2024223899A1 (en) 2023-04-28 2024-10-31 Medimmune Limited B7-h4 therapeutic binding molecules for the treatment of cancer
CN121194800A (zh) * 2023-05-12 2025-12-23 百奥赛图(北京)医药科技股份有限公司 接头化合物和配体-药物缀合物及其制备方法和用途
CN119074949A (zh) 2023-06-05 2024-12-06 江苏迈威康新药研发有限公司 抗b7-h3的抗体或其片段以及靶向b7-h3的抗体药物偶联物
WO2025027472A2 (en) 2023-07-31 2025-02-06 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
TW202540115A (zh) * 2023-11-16 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 一種氘代喜樹鹼化合物及其製備和應用
WO2025167742A1 (zh) * 2024-02-06 2025-08-14 四川科伦博泰生物医药股份有限公司 抗体药物偶联物及其制备方法和用途
WO2025167743A1 (zh) * 2024-02-06 2025-08-14 四川科伦博泰生物医药股份有限公司 抗体药物偶联物及其制备方法和用途
WO2025191470A1 (en) 2024-03-12 2025-09-18 Astrazeneca Ab Processes and compounds for the preparation of topoisomerase i inhibitor linker-payloads

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
JP2754022B2 (ja) * 1988-11-18 1998-05-20 第一製薬株式会社 カンプトテシン類縁体
JP3024013B2 (ja) * 1990-08-14 2000-03-21 杏林製薬株式会社 フルオロエチルカンプトテシン誘導体
US5637770A (en) 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
EP0811603B1 (en) 1995-02-22 2002-11-13 Daiichi Pharmaceutical Co., Ltd. Aminotetralone derivatives and process for producing the same
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
JPH1095802A (ja) * 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd カンプトテシン誘導体
IN189180B (es) 1997-07-09 2003-01-04 Chong Kun Dang Corp
AR030207A1 (es) 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
DE60230097D1 (de) 2001-05-08 2009-01-15 Mitsui Chemicals Polyurethanes Verfahren zur herstellung von 1,5-diaminonaphthalinen
HUP0500062A3 (en) 2001-11-30 2012-12-28 Chugai Pharmaceutical Co Ltd Fused camptothecin derivatives, process for their preparation and pharmaceutical compositions thereof
CN1777611A (zh) 2003-02-21 2006-05-24 中外制药株式会社 制备六环喜树碱衍生物的方法
CA2563502A1 (en) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
CN103313992B (zh) 2011-01-12 2016-04-27 天堃医药科技（杭州）有限公司 具有hdac抑制作用的喜树碱衍生物
CN102850400A (zh) 2011-06-30 2013-01-02 周文强 喜树碱衍生物及其制备方法、药物组合物与用途
KR102853456B1 (ko) * 2012-10-11 2025-09-01 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
US9962452B2 (en) 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
AU2014354643B2 (en) 2013-11-27 2020-03-05 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
KR102444529B1 (ko) 2013-12-25 2022-09-19 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
ES2895254T3 (es) 2014-01-31 2022-02-18 Daiichi Sankyo Co Ltd Conjugado de fármaco-anticuerpo dirigido contra HER2
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
AU2015245122B2 (en) 2014-04-10 2019-10-24 Daiichi Sankyo Company, Limited Anti-HER3 antibody-drug conjugate
WO2016053107A1 (en) 2014-10-03 2016-04-07 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
WO2016123582A1 (en) 2015-01-30 2016-08-04 Sutro Biopharma, Inc. Hemiasterlin derivatives for conjugation and therapy
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HUE061408T2 (hu) 2015-06-29 2023-06-28 Daiichi Sankyo Co Ltd Eljárás antitest-gyógyszer konjugátum szelektív elõállítására
MA43354A (fr) * 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
AU2017341000B2 (en) 2016-10-07 2024-11-28 Daiichi Sankyo Company, Limited Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate
KR20190083654A (ko) 2016-11-10 2019-07-12 메디뮨 엘엘씨 Asct2에 특이적인 결합 분자 및 이의 용도
WO2018110515A1 (ja) 2016-12-12 2018-06-21 第一三共株式会社 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
WO2018159582A1 (ja) 2017-02-28 2018-09-07 学校法人近畿大学 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法
TW202530220A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
CN109106951A (zh) 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
CN108853514B (zh) 2017-08-18 2022-07-22 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
KR102679892B1 (ko) * 2019-03-29 2024-07-02 메디뮨 리미티드 화합물 및 이의 접합체

Also Published As

Publication number Publication date
US11446292B2 (en) 2022-09-20
IL286291B1 (en) 2024-12-01
CN118240003A (zh) 2024-06-25
JP2023065346A (ja) 2023-05-12
EP3946464A1 (en) 2022-02-09
JP7210770B2 (ja) 2023-01-23
KR20230023814A (ko) 2023-02-17
TWI886667B (zh) 2025-06-11
US20200306243A1 (en) 2020-10-01
PL3946464T3 (pl) 2022-12-19
EP4176904A1 (en) 2023-05-10
CN113631196A (zh) 2021-11-09
JP2022528851A (ja) 2022-06-16
CN117263948A (zh) 2023-12-22
WO2020200880A1 (en) 2020-10-08
UA129129C2 (uk) 2025-01-22
MX2021011812A (es) 2021-10-22
CA3133757A1 (en) 2020-10-08
KR20210144845A (ko) 2021-11-30
HRP20221280T1 (hr) 2022-12-23
KR20240104214A (ko) 2024-07-04
TW202104235A (zh) 2021-02-01
AU2020252034A1 (en) 2021-11-11
CO2021014566A2 (es) 2021-11-19
IL286291B2 (en) 2025-04-01
TWI826676B (zh) 2023-12-21
US20220211863A1 (en) 2022-07-07
SG11202110524VA (en) 2021-10-28
IL286291A (en) 2021-10-31
CL2021002498A1 (es) 2022-06-03
SMT202200439T1 (it) 2023-01-13
PT3946464T (pt) 2022-11-16
JP7680658B2 (ja) 2025-05-21
KR102679892B1 (ko) 2024-07-02
TW202423947A (zh) 2024-06-16
BR112021018986A2 (pt) 2022-01-18
DK3946464T3 (da) 2022-10-31
ES2930295T3 (es) 2022-12-09
CN113631196B (zh) 2024-03-15
ZA202106612B (en) 2022-08-31
KR102498681B1 (ko) 2023-02-09
EP3946464B1 (en) 2022-08-31
AU2020252034B2 (en) 2024-02-01
CN118221763A (zh) 2024-06-21
LT3946464T (lt) 2022-11-10
RS63715B1 (sr) 2022-11-30
CN117263948B (zh) 2024-11-22
CR20210541A (es) 2021-12-20
PH12021552363A1 (en) 2022-09-05
HUE060364T2 (hu) 2023-02-28
US20210322401A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
ECSP21078204A (es) Compuestos y conjugados de estos
ECSP22064855A (es) Compuestos y conjugados de estos
AR119754A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CR9232A (es) Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas
CO6351724A2 (es) Inhibidores de cmet
GT201200046A (es) Conjugados de dímeros de pirrolo[1,4] benzodiazepina como agentes anticancerosos
CR11661A (es) Derivado heterociclico fusionado y su uso
CU20110078A7 (es) Compuestos de carbazol
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
CY1110893T1 (el) Διαδικασιες και ενδιαμεσες ενωσεις για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv
CR9442A (es) Nuevos compuestos farmaceuticos
PA8666701A1 (es) Nueva sal y polimorfos del inhibidor de la dpp-iv
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
CR10230A (es) Proceso para la síntesis convergente de los derivados de caliqueamicina
CR9872A (es) Diazepinoquinolinas, su sintesis e intermediarios
AR057305A1 (es) Proceso para la preparacion de derivados de sulfamida
CR9670A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
ECSP099783A (es) Nuevos compuestos ligandos del receptor de la adenosina a3
ECSP088251A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
UY29798A1 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CR11828A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
ECSP077979A (es) Potenciadores del receptor ampa
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos